Ono Pharmaceutical (OTCMKTS:OPHLY – Get Free Report) is expected to issue its results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.0913 per share and revenue of $725.78 million for the quarter.
Ono Pharmaceutical Stock Down 0.5%
Ono Pharmaceutical stock opened at $5.25 on Tuesday. Ono Pharmaceutical has a 52-week low of $3.82 and a 52-week high of $5.75. The company has a fifty day simple moving average of $5.04 and a 200-day simple moving average of $5.01.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its activities focus primarily on areas of high unmet medical need, including oncology, immunology, neurology and other specialty-care fields.
The company’s best-known product is Opdivo (nivolumab), an immune checkpoint inhibitor used in the treatment of multiple cancers. Ono has also developed or commercialized other specialty medicines, including treatments for cancer and immune-related conditions, through internal research and collaborations with pharmaceutical companies in Japan and overseas.
Ono Pharmaceutical traces its origins to 1717, when it began as a drug wholesaler in Osaka, and was incorporated in its modern corporate form in 1947.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
